0
ARTICLE |

Kaposi's Sarcoma, Vascular Permeability, and Scientific Integrity FREE

Joseph L. Bryant, DVM
JAMA. 1994;272(12):921-921. doi:10.1001/jama.1994.03520120026022
Text Size: A A A
Published online

To the Editor.  —I write in reference to the article by Dr Witte and colleagues.1My interest in the article stems from the fact that during the past 2 years I have been working closely in collaboration with three different investigators working with KS in Dr Gallo's laboratory. Their studies include injecting cultured cell lines of KS into nude mice and also administering EB dye via the tail vein in nude mice. As a laboratory-animal veterinarian with more than 20 years of experience working with rodents, I believe I can state that I have become highly proficient in inoculating mice. Although I did not perform the experiments to which the article refers, I have performed and am currently performing similar experiments using EB dye.I would like to share with you my experience injecting EB dye via the tail vein in mice. If the mice are not anesthetized during

REFERENCES

Witte MH, Borgs P, Way DL, Bernas M, Ramirez G Jr, Witte CL.  Kaposi's sarcoma, vascular permeability, and scientific integrity. JAMA . 1994;;271:1769-1771.
Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, Sekiguchi M, Gallo RC.  Inhibition of development of Kaposi's sarcoma—related lesions by a bacterial cell wall complex. Science . 1992;;255:1437-1440.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Witte MH, Borgs P, Way DL, Bernas M, Ramirez G Jr, Witte CL.  Kaposi's sarcoma, vascular permeability, and scientific integrity. JAMA . 1994;;271:1769-1771.
Nakamura S, Sakurada S, Salahuddin SZ, Osada Y, Tanaka NG, Sakamoto N, Sekiguchi M, Gallo RC.  Inhibition of development of Kaposi's sarcoma—related lesions by a bacterial cell wall complex. Science . 1992;;255:1437-1440.
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.